Find the latest press releases and communications on our news section.
Meet Miranda de Jager, Treeway’s CMC consultant. She joined the company in 2017 as a chemistry, manufacturing and controls consultant. Miranda de Jager joined with plenty of experience and immense motivation and commitment to the cause of developing treatment for ALS. Throughout her career, the...
With the licensing agreement between Treeway and Ferrer in place, FNP122 (formerly TW001) has now entered clinical stage phase III with the initiation of the ADORE study (ALS Deceleration study with Oral Edaravone). In a large-scale double-blind placebo-controlled clinical trial, Ferrer will test...
Ferrer announces first patient enrollment of FNP122 in ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis treatment
Barcelona, November 9th, 2021 – Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has today announced the next major milestone in its mission to develop transformative therapies for Amyotrophic Lateral...
Ferrer and Treeway enter into licence agreement for the development and commercialisation of TW001/FNP122 for Amyotrophic Lateral Sclerosis
Ferrer and Treeway announced they have entered into a licence agreement for the development and commercialisation of an oral formulation of edaravone (TW001/FNP122)[i] for ALS in certain territories, including Europe and some Asian countries.
On Thursday April 18, Treeway’s CEO Inez de Greef is a speaker at the Rare Diseases Symposium.
Study suggests that novel oral formulation of edaravone improves bioavailability while remaining well tolerated.
This week, the Australian Motor Neurone Disease Symposium takes place in Melbourne, Australia.
Op maandag 9 april wordt in samenwerking met het Jeroen Bosch Ziekenhuis een maatschappelijk symposium georganiseerd rondom het thema ALS.
We are extremely proud on winning The Shay Rishoni Patient Impact Award.